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Abstract
Although mesenchymal stem cells (MSCs) have been implicated as stromal components of several 
cancers, their ultimate contribution to tumorigenesis and their potential to drive cancer stem cells, 
particularly in the unique microenvironment of human brain tumors, remains largely undefined. 
Consequently, using established criteria, we isolated glioma-associated-human MSCs (GA-
hMSCs) from fresh human glioma surgical specimens for the first time. We show that these GA-
hMSCs are nontumorigenic stromal cells that are phenotypically similar to prototypical bone 
marrow-MSCs. Low-passage genomic sequencing analyses comparing GA-hMSCs with matched 
tumor-initiating glioma stem cells (GSCs) suggest that most GA-hMSCs (60%) are normal cells 
recruited to the tumor (Group 1 GA-hMSCs), although, rarely (10%), GA-hMSCs may 
differentiate directly from GSCs (Group 2 GA-hMSCs) or display genetic patterns intermediate 
between these groups (Group 3 GA-hMSCs). Importantly, GA-hMSCs increase proliferation and 
self-renewal of GSCs in vitro, and enhance GSC tumorigenicity and mesenchymal features in 
vivo, confirming their functional significance within the GSC niche. These effects are mediated by 
GA-hMSC-secreted interleukin-6, which activates STAT3 in GSCs. Our results establish GA-
hMSCs as a potentially new stromal component of gliomas that drives the aggressiveness of 
GSCs, and point to GA-hMSCs as a novel therapeutic target within gliomas.
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INTRODUCTION
Although much attention is given to cell-autonomous mechanisms of tumor progression, 
non-cell-autonomous mechanisms, particularly interactions between tumor cells and stromal 
cells, are increasingly recognized as important contributors to tumor growth and resistance 
to therapy [1,2]. As in other cancers, glioblastoma (GBM), the most aggressive adult 
primary brain tumor, is maintained by a stem cell-like population of cells, called glioma-
initiating cells (GICs) or glioma stem cells (GSCs), which have been the focus of intense 
research due their capacity for tumorigenicity, therapeutic resistance, and recurrence [3,4]. 
Although the cell-autonomous mechanisms of GSC growth have been extensively explored, 
the interaction of GSCs with the cells of the surrounding stroma remains poorly defined, 
despite the potential of non-GSC-autonomous mechanisms to contribute to the aggressive 
behavior of glioblastomas.
Compared with other cancers, the stroma of GBMs is not well understood, due to the 
uniqueness of the brain [1], and it is thought to be composed of reactive astrocytes, 
endothelial cells, and immune cells [1,2]. However, the contribution of other cell types, 
particularly human mesenchymal stem cells (hMSCs), has only begun to be explored [5]. 
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hMSCs are adult, nonhematopoietic, multipotent progenitor cells, originally isolated from 
the bone marrow, which are traditionally characterized in vitro by their plastic adherence, 
trimesenchymal differentiation, and expression of a panel of distinguishing surface markers 
[6,7]. Although bone marrow-derived hMSCs (BM-hMSCs) are the prototypical MSCs, it 
has recently been suggested that MSCs may reside in almost all tissues, including the brain, 
typically around blood vessels, as pericytes [8–10]. MSCs have been implicated in diverse 
physiological roles [11,12], including maintaining stem cell self-renewal and proliferation 
[13]. MSCs are also known for their ability to migrate to zones of tissue injury, and several 
studies have implicated MSCs among the bone marrow-derived cells that may be recruited 
into tumors [8,14–17].
We and others have shown that BM-hMSCs harvested from the bone marrow of normal 
volunteers and numericially expanded ex vivo are capable of homing to gliomas after 
systemic administration and can be engineered to deliver therapeutic agents to glioblastomas 
[18–20]. This tropism of exogenous BM-hMSCs for gliomas prompted us to hypothesize 
that endogenous hMSCs (i.e., hMSCs from the bone marrow or local MSCs residing in the 
brain) might also have a tropism for human gliomas and, therefore, may be a stromal 
component of GBMs that can alter the biological behavior of GSCs in situ. We reasoned that 
if this hypothesis were true, we should be able to isolate hMSC-like cells from human 
glioma surgical specimens and demonstrate that the isolated hMSC-like cells alter the 
biology of tumor-initiating GSCs. To address this hypothesis, we took a translational 
approach using fresh surgical specimens and now show that human gliomas harbor hMSC-
like cells (referred to as glioma-associated-hMSCs (GA-hMSCs)), which can be classified 
into three genetic groups, and that these GA-hMSCs enhance the stemness, proliferation, 
and tumorigenicity of GSCs through the IL-6/STAT3 pathway. These studies identify GA-
hMSCs as a heretofore unrecognized cellular component of the stroma of glioblastomas and 
suggest new therapeutic strategies for treating GBMs.
METHODS
Surgical brain tumor specimens
Surgical specimens taken from patients with human gliomas were obtained fresh from the 
operating room after participating patients granted written consent, according to an IRB 
approved protocol (LAB04-0001). Specimens were reviewed by a neuropathologist to assess 
the grade and type of tumor before assays were performed. Cell isolation procedures were 
typically undertaken within 4 hours of tumor removal.
Isolation of GA-hMSCs
To isolate cells resembling hMSCs, specimens were processed according to the protocol of 
Pittenger et al. [21], used for isolating bone marrow-derived MSCs with modifications for 
whole tissues. In brief, tumor specimens were washed twice in serum-free minimal essential 
medium–alpha (MEM-α, Mediatech, Herndon, VA), minced, dissociated, and passed 
through a series of cell strainers. Single cells were resuspended in standard “MSC Media,” 
consisting of MEM-α plus 10% certified fetal bovine serum (FBS; Lonza, Wlkersville, 
MA), 2 mM L-glutamine (50 U/ml, Mediatech), and penicillin/streptomycin (50 mg/ml, 
Hossain et al. Page 3
Stem Cells. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Flow Laboratories, Rockville, MD), and plated at a density of 2 × 106 live cells per 75 cm2 
flask. After 24 hours, nonadherent cells were removed by two washes with phosphate-
buffered saline (PBS; Mediatech), and adherent cells were cultured until they reached 
confluence. Cells were trypsinized (0.25% trypsin with 0.1% EDTA) and subcultured at a 
density of 5000 cells/cm2. These cells were cultured continuously through multiple 
passages. Cell cultures were observed with an inverted phase-contrast microscope (Axiovert 
200; Zeiss, Hallbergmoos, Germany). Photographs of cells were taken with a digital camera 
(AxioCam MRc, Zeiss), using Xcap-Plus version 2.1 software (Epix Inc., Buffalo Grove, 
IL) at each passage.
Isolation of GSCs
GSCs were also isolated from surgical specimens according to the method of Singh et al. 
[3]. Briefly, tumor specimens were dissociated as above and resuspended in standard 
“Neurosphere Media,” (NSC media), consisting of DMEM/F12 (Mediatech) with B27 (x1, 
Invitrogen), bFGF (20 ng/ml, Sigma), and EGF (20 ng/ml, Sigma). Cells were cultured as 
neurospheres and passaged every 5–7 days, based on sphere size.
Flow cytometry analysis
To investigate the surface expression profile, cells were trypsinized and counted in a Vi-Cell 
machine (Version 1.01; Beckman Coulter Inc., Fullerton, CA). Cells were washed in PBS, 
and pellets were resuspended in fluorescent-activated cell sorting (FACS) buffer (PBS with 
10% FBS) at a concentration of 5 × 105 cells per 100 µl. These single-cell suspensions were 
incubated at 4°C for 30 minutes with phycoerythrin (PE)-, fluorescein isothiocyanate 
(FITC)-, Alexa Fluor 647-, or allophycocyanin (APC)-conjugated antibodies against human 
CD105, CD90, (both from eBioscience, San Diego, CA), CD73, CD34, CD45 (all from BD 
Bioscience, San Jose, CA) and CD133 (Miltenyi Biotech, Auburn, CA). Flow cytometry 
analysis was performed using a FACScalibur (BD Biosciences) flow cytometer equipped 
with BD CellQuest Pro version 5.1.1 software (Apple, Cupertino, CA), with 20,000 events 
recorded for each sample.
Differentiation protocols
Cells were differentiated into osteocytes, adipocytes, and chondrocytes using specific 
osteogenic, adipogenic, or chondrogenic induction and maintenance media, respectively 
(Lonza (Walkersville, MA), and used according to the manufacturer’s suggested protocols 
for differentiation of human bone marrow-derived MSCs. To analyze the results of 
osteogenic differentiation, cells were stained with 40 mM Alizarin Red. Calcium deposits 
were visible within osteocytes. To analyze the results of adipogenic differentiation, cells 
were stained with Oil Red O. Adipogenic differentiation was verified by lipid vacuoles 
visible within cells. For chondrogenic differentiation, pelleted specimens were formalin 
fixed, paraffin-embedded, and thin sections were slide-mounted and stained for 
glycosaminoglycans using Safranin O staining. In each case, BM-hMSCs were used as a 
positive control.
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Chromosome 10 loss of heterozygosity (LOH) analysis
The multiplex polymerase chain reaction (PCR) was performed according to the standard 
protocol. In brief, 1–4 µl (approx. 20–100 ng) of purified genomic DNA from GSCs and 
GA-MSCs, in each case, was mixed with 5 µl Multi Primer Mix (PE Applied Biosystems), 
containing all 6 PCR primer pairs for the selected microsatellite markers. Water was added 
to make a final volume of 25 µl. PCR was performed using a Perkin Elmer thermocycler. 
The PCR conditions were as follows: after an initial 2 min denaturation step at 94°C, 30 
amplification cycles were performed, each consisting of a 10 s step at 94°C, a 30 s step at 
55°C, and a 30 s elongation step at 72°C. Amplification was completed with a final 
incubation step at 72°C for 7 min. The amplified PCR products were analyzed using the 
automated ABI PRISM sequencer model 310 Genetic Analyzer.
Low-pass whole-genome sequencing and copy number variant analyses
Whole-genome sequencing was performed on 10 GSCs and their matched GA-hMSC pairs 
and 2 unmatched GA-hMSCs using the Illumina HiSeq2000 platform. Paired-end 
sequencing was performed on genomic DNA fragmented to an average size of 160bp. We 
determined copy number variation using BICSeq [22]. The BM-hMSC was used as the 
common reference.
Immunofluorescence
Sections of formalin-fixed paraffin-embedded human GBM surgical specimens were 
deparaffinized with xylene and rehydrated through a graded alcohol series. The heat-induced 
antigen retrieval was carried out in a microwave for 4 min at 100% power and 15 min at 
10% power, using citrate buffer at pH 6.0. Nonspecific staining was blocked by 
preincubation of these sections in PBS containing 5% IgG-free BSA (Jakson 
ImmunoResearch Laboratories) for 1 hour at room temperature. Primary antibodies used 
were as follows: mouse anti-CD31 monoclonal antibody 1:500 (Abcam), rabbit anti-CD31 
polyclonal antibody 1:50 (Abcam), rabbit anti-CD105 polyclonal antibody 1:50 (Abcam), 
mouse anti-CD105 monoclonal antibody 1:50 (Abcam), rabbit anti-CD133 polyclonal 
antibody 1:150 (Abcam), rabbit anti-PDGFRB polyclonal antibody 1:150 (R&D), goat anti-
PDGFRB 1:100 (R&D), rabbit anti-ADAM12 antibody 1:100 (Abcam). After primary 
antibody incubation overnight at 4°C, sections were rinsed several times with PBS and 
incubated with appropriate secondary antibodies at room temperature for 30 min. The 
secondary antibodies used were as follows: Alexa Fluor 488- or Alexa Fluor 594-conjugated 
donkey anti-mouse, donkey anti-rabbit, and donkey anti-goat antibodies (Invitrogen). After 
washes in PBS, the sections were counterstained with DAPI and mounted with anti-fade 
mounting medium. For antigen specificity controls, antibody diluents were used to replace 
either primary or secondary antibody in the corresponding incubation steps.
Coculture, cell proliferation assay, cell cycle assay and immunocytochemistry
For coculture, 24 well ThinCert™ cell culture inserts with translucent membranes and 0.4 
µm pores were used. GA-hMSCs or human brain microvascular endothelial cells (hBMECs) 
suspended in MSC medium containing 0 (control) or 105 cells were pipetted into the inner 
side of the membrane. The cells were allowed to adhere overnight at 37°C in an atmosphere 
Hossain et al. Page 5
Stem Cells. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
of 95% air/5% CO2. Cells were washed three times and subsequently, the insert was placed 
in the well of 24-well plates prefilled with complete NSC medium. GSC suspensions 
containing 105 cells were added to the bottom well. Medium from upper wells was removed 
and fresh medium was added on each alternate day. Cocultures were maintained for 5–7 
days at 37°C in an atmosphere of 95% air/5% CO2. The Water-Soluble Tetrazolium salts 
(WST-1) assay was performed with the Cell Proliferation Kit I (Roche). In brief, inserts 
containing GA-hMSCs or hBMECs were removed and 100 µl of WST-1 solution were 
added to each well of a 24-well plate. After an incubation of 4 h at 37 °C in an atmosphere 
of 95% air/5% CO2, 100 µl of the solution from the well were transferred to a clear bottom 
96-well plate. The absorbance was measured at 450 nm. The 5-ethynyl-2´-deoxyuridine 
(EdU) assay was performed according to the manufacturer’s protocols (Invitrogen, CA). 
Immunocytochemical analysis was performed according to the protocol described at 
www.jove.com. In brief, spheres in the bottom wells were fixed with 500 µl 4% PFA, 
washed twice with 500 µl PBS, and made permeable for 5 min with 500 µl 0.3% Triton/PBS. 
After washing with PBS, nonspecific protein binding sites were blocked with 500 µl 5% 
BSA in PBS for 1 h. Cells were washed with PBS and incubated for 1 h with 100 µl of 
different antibodies at 1:50 dilution and incubated overnight. After washes with PBS, the 
cells were incubated for 1 h with 100 µl Alexa 488 anti-IgG antibody (1:1000 in 1% BSA/
PBS). Nuclei were counterstained with DAPI.
Animal Studies
Male athymic nude mice (nu/nu) were purchased from the Department of Experimental 
Radiation Oncology, The University of Texas M.D. Anderson Cancer Center (Houston, 
TX). Intraperitoneal (IP) injections of ketamine (100mg/kg)/xylazine (10mg/kg) were used 
to anesthetize animals in all experiments. All animal manipulations were performed in the 
veterinary facilities in accordance with institutional, state, and federal laws and ethics 
guidelines under an approved protocol. Intracranial and flank xenografting: Intracranial 
xenografts of GSCs and GA-hMSCs were implanted using a guide screw and a multiport 
microinfusion syringe pump (Harvard Apparatus, Holliston, MA), as previously described 
[18,23]. For GSC-only experiments, GSCs were cocultured with GA-hMSCs as indicated in 
the text, and after 5 days, only GSCs were collected and injected into the brain at the 
indicated number of cells in 5 µl of cell suspension. For intracranial mixing experiments, 
GSCs and GA-hMSCs were combined at the indicated ratios and injected intracranially (5 µl 
cell suspension) into the caudate nucleus via a guide screw. For subcutaneous experiments, 
GSCs and GA-hMSCs were combined at the indicated ratios and injected subcutaneously 
(100µl cell suspension) into the left flank.
Cytokine antibody array
Conditioned medium was probed for its cytokine profile using the Human Angiogenesis 
Array C1000 kit according to the manufacturer’s instructions (RayBiotech). Briefly, 
membranes were blocked with a blocking buffer, and 2 ml of pooled serum samples were 
added and incubated at 4°C overnight. Membranes were washed, and 1 ml of primary biotin-
conjugated antibody was added and incubated at room temperature for 2 h. The membranes 
were then incubated with 2 ml of horseradish peroxidase–conjugated streptavidin at room 
temperature for 30 min, and cytokine presence was detected by chemiluminescence.
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ELISA assays
The expression levels of IL6, IL8, Gro-α and MCP1 in the conditioned medium were 
quantified using an ELISA kit (Quantikine®, R&D Systems, Minneapolis, MN) according 
to manufacturer’s protocol. Briefly, cells were plated at 105 cells/ ml in serum-free medium, 
and 48 hrs later the conditioned medium was collected and assayed.
Plasmids and lentivirus preparation
GP130-specific shRNA constructs were purchased from a commercial source (Open 
Biosystems). Lentivirus was prepared according to standard protocols with modification. In 
brief, lentiviruses were prepared using 293FT cells (Invitrogen) transfected with packaging 
vectors (psPAX2; Addgene, Cambridge, MA), envelope vectors (pMD2.G; Addgene 
Cambridge, MA.), and lentiviral vectors, using Lipofectamine 2000 transfection reagent 
(Invitrogen). For infection of GSCs, spheres were first dissociated with Accutase (Sigma), 
and lentiviruses were added typically 10 MOI in NSC medium containing polybrene (8 
µg/ml) in a volume of 2–5 × 105 cells/ml, and incubated overnight. Cells were washed after 
8–12h and resuspended in NSC medium containing puromycin (1 µg/ml) for selection.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism. Unless specifically noted, all data 
are representative of >3 separate experiments. Error bars represent the SEM, were calculated 
using Prism, and are derived from triplicate experimental conditions. Specific statistical tests 
used were paired and unpaired t tests, and all p values < 0.05 were considered statistically 
significant. Graphpad Prism was used to compare two survival curves using the log-rank 
test.
RESULTS
CD105+/CD31 cells can be identified in GBM specimens
Because MSCs are defined by in vitro assays [7], identifying MSCs in situ is difficult due to 
the lack of specific antibodies to the common MSC surface antigens. Nevertheless, to begin 
to explore whether hMSC-like cells reside in glioblastomas in situ, we performed 
immunohistochemical (IHC) analysis for CD105, the most consistent hMSC marker [7], on 
formalin-fixed specimens of human GBMs (SP240, SP237, and SP248). Because endothelial 
cells also stain for CD105, we costained for CD31, an endothelial marker. Confocal 
microscopy revealed a population of CD105+/CD31+ cells that were probably endothelial 
cells (Fig. 1a). However, we also identified CD105+/CD31- cells (Fig. 1a) that were located 
both around endothelial cells and distant from vessels, suggesting that hMSC-like cells 
reside in both perivascular sites, as pericytes [8], and in tumor tissue proper. To assess 
whether the CD105+/CD31- cells met other surface marker criteria for MSCs, we 
immunostained for CD105 and PDGFRβ, which is known to be expressed on 30–40% of 
BM-hMSCs in vitro [8,11,24]. Subsets of PDGFRβ+ cells were positive for CD105, and 
these CD105+/PDGFRβ+ cells resided in stromal areas both near and away from blood 
vessels (Fig. 1b). Importantly, CD105+ positive cells were not positive for the established 
pericyte marker NG2, indicating that the CD105+ cells were not mature pericytes (Fig. 1c).
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We also stained for both CD105 and CD133, a known GSC marker (Fig. 1d). Only rare 
colocalization of CD105 and CD133 was seen, indicating that MSCs and GSCs were distinct 
populations that were nevertheless present in the same niche.
Recent studies suggest that ADAM12 is a marker of activated hMSCs [25,26]. 
Immunostaining for ADAM12, and either CD105 or CD31, revealed a distinct population of 
CD105+/ADAM12+/CD31- cells, further supporting the notion that MSC-like cells exist 
within human gliomas in situ (Fig. 1e,f).
hMSCs are defined not only by CD105 expression, but also by CD73 and CD90 expression. 
However, antibodies against CD73 and CD90 are not effective in IHC analysis. 
Consequently, to further demonstrate the potential of MSCs to reside in GBMs in situ, we 
assessed fresh glioma specimens using FACS analysis for the presence of triply positive 
(CD105+/CD73+/ CD90+) cells before culturing. SP231, SP240, and SP262 harbored 
13.4%, 1%, and 9.1% triply positive cells, respectively (Fig.1g), indicating that glioma 
specimens harbor cells with the surface characteristics of hMSCs.
MSC-like cells can be cultured from human gliomas
Our immunohistochemical and flow studies suggested the presence of MSCs in human 
gliomas, but MSCs are officially defined by in vitro criteria [7]. Consequently, we sought to 
isolate MSC-like cells from human glioma surgical specimens using the culture conditions 
and criteria identical to that of BM-hMSCs, which are the prototypical hMSCs [7]. We 
originally cultured 32 consecutive surgical glioma specimens using the same protocol used 
for isolating hMSCs from bone marrow. We then assayed the isolated cells using the criteria 
for defining MSCs established by the International Society of Cellular Therapy [7], namely: 
1) adherence to plastic with spindle shape morphology; 2) positive expression of CD105, 
CD73, and CD90, with negative expression of CD45 and CD34; and 3) trimesenchymal 
differentiation into adipocytes, chondrocytes and osteocytes. We also assayed for the GSC 
markers CD133, and in some cases, CD15, to prove that the cells did not have markers 
indicative of GSCs. Of the original 32 cultures, 9 (28%) met all three criteria (Table 1, cases 
1–9; and Fig. 1h–j), and 12 cultures met all criteria except that they differentiated into two 
mesenchymal phenotypes (Table 1, cases 10–21). Therefore, 21 (66%) specimens had triply 
positive surface expression and could be differentiated into multiple (>2) mesenchymal cell 
types. We refer to these isolated cells as glioma-associated-hMSCs (GA-hMSCs).
Of these 21 cultures, all have been passaged multiple times (doubling time typically is 72 
hrs), with several maintained until passage 30 (Supplementary Fig. 1a). We analyzed a 
subset of these GA-hMSCs for other markers that are commonly expressed MSCs (CD146, 
PDGFRβ, STRO-1, CD44) and found that these GA-hMSCs expressed levels of these 
markers similar to the levels expressed on prototypical BM-hMSCs (Supplementary Table 
1). In addition, the GSC marker CD15 was not present on tested GA-hMSCs; specifically, 
GA-MSC0818, GA-hMSC240, GA-hMSC100907 had 0.9%, 0.2% and 0.6% CD15 
expression, respectively, and BM-hMSCs had 1.5% CD15 expression.
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GA-hMSCs are distinct from GSCs
We were interested in determining whether GA-hMSCs were distinct from GSCs. Therefore, 
we used the methods described by Singh et al. to isolate GSCs from our surgical specimens 
[3,27]. We were able to culture GSCs from five of our original 21 specimens from which we 
had also isolated GA-hMSCs, giving us 5 matched pairs in which GSCs and GA-hMSCs 
were grown from the same tumor specimen (Table 2 pairs 1–5, and marked with asterisk in 
Table 1). We also isolated GSCs from several other “unmatched” specimens (Table 2, 
Bottom).
In order to expand our pool of matched pairs, we cultured a second series of surgical 
specimens in order to specifically obtain both GA-hMSCs and GSCs from the same 
specimen. This effort resulted in another 5 matched pairs of GA-hMSCs and GSCs (Table 1: 
cases 22–26 and Table 2: pairs 6–10). Consistent with our original series, the GA-hMSCs 
from this second series met the ISCT criteria of hMSCs, as they grew as spindle shaped 
adherent cells, expressed high levels of CD105, CD73, and CD90, and differentiated into 
mesenchymal phenotypes.
When we compared the GA-hMSCs with the GSCs we found that GSCs grew as 
nonadherent spheroids when cultured in typical neurosphere media, consistent with previous 
reports. This morphology was distinct from the adherent growth of GA-hMSCs 
(Supplementary Fig. 1b). In addition, the GSCs typically did not express high levels of the 
three canonical surface markers, CD105/CD90/CD73, suggesting that they are 
phenotypically distinct from GA-hMSCs (Table 2). The GSCs expressed variable amounts 
of CD133, a marker that is frequently, but not invariably, expressed on GSCs, whereas the 
GA-hMSCs did not express this marker (Table 2). Although GA-hMSCs did not express 
CD15 (see above), 21.6% of cells in sample GSC0818 expressed this marker. Most 
importantly, GSCs were highly tumorigenic (as expected), whereas no GA-hMSCs were 
tumorigenic, consistent with their role as stromal cells. Implanting 106 cells from each of the 
original 21 GA-hMSC cultures and from the additional 5 GA-hMSC cultures into the brains 
of SCID mice (N = 3–5mice/cell line) did not result in tumors, in any case (Fig. 1l; Table 1 
and Table 2; Supplementary Figure 1c). In contrast, implantation of as few as 104 GSC-cells 
from each of the matched pairs and the additional unmatched GSCs resulted in highly 
invasive tumors similar to human GBMs in all cases (Fig. 1l; Table 2, Supplementary Figure 
1c). Therefore, in all 10 matched pairs, GSCs formed GBMs in vivo and the corresponding 
GA-hMSCs did not. In addition no unmatched GA-hMSCs were able to form tumors, 
whereas all unmatched GSCs could initiate tumors (Table 1 and Table 2). Because the 
culture medium of GA-hMSCs was different from that of GSCs, we determined whether 
growing GSCs in MSC medium eliminated the tumorigenicity of the GSCs. Although GSCs 
became adherent after culture in MSC medium (Supplementary Fig. 1b), the GSCs did not 
lose their tumorigenicity after being cultured in it (Supplementary Fig. 1c, d). Additionally, 
whereas GA-hMSCs (like BM-hMSCs) do not express the neural stem cell marker SOX2, 
GSCs robustly express SOX2 (and Musashi) and maintain this expression even when grown 
in MSC medium (Supplementary Fig. 1e, f). Together, these results suggest that GA-hMSCs 
are a stromal population of cells in GBMs and are phenotypically distinct from GSCs based 
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on their in vitro growth characteristics, surface marker expression, tumorigenicity, and 
expression of neural stem cell proteins.
We next asked whether GA-hMSCs were genetically distinct from GSCs. Specifically, we 
were interested in determining whether the GA-hMSCs were stromal cells recruited into the 
tumor or whether they were stromal cells that differentiated from GSCs. We reasoned that if 
the GA-hMSCs were differentiation products of GSCs, then genetic alterations found in the 
GSCs should also be found in the GA-hMSCs, whereas if the GA-hMSCs were recruited 
into the tumor from non-GSC sources, they would not display the genetic changes seen in 
GSCs. Tumor suppressor PTEN is located on chromosome 10 (ch10), and deletions of losses 
of ch10 are common in GBM specimens. Previous work has shown that GSCs also almost 
invariably demonstrate loss of chromosome 10, reflecting the loss in the tumors from which 
the GSCs were derived [28]. In addition, the known glioma oncogene EGFR is located on 
chromosome 7, and GSCs commonly show amplification of chromosome 7, similar to GBM 
specimens.
As a first step in analyzing the genetic make-up of GSCs and GA-hMSCs, we assessed LOH 
of chromosome 10 in BM-hMSCs (as a control) and in three randomly selected paired 
GSCs/GA-hMSCs and in two randomly selected unpaired GA-hMSC samples, using Gene 
scan technology (Fig. 1k and Supplementary Table 2). As expected, BM-hMSCs showed an 
intact chromosome 10, consistent with their status as a genetically normal cell type. In the 
three paired cases, the GSC line showed loss of chromosome 10, whereas the GA-hMSCs in 
each case showed two chromosome 10 alleles. In addition, we could verify an intact 
chromosome 10 in both of the unpaired GA-hMSC samples. These results suggested that 
most GA-hMSCs are distinct from GSCs and do not harbor losses in chromosome 10 that 
are commonly seen in most GSCs.
In order to more comprehensively characterize the genetic changes in GA-hMSCs and to 
compare these changes with GSCs, we performed low-pass whole-genome sequencing on 
our 10 matched pairs of GSCs and GA-hMSCs and on two additional unpaired GA-hMSCs 
(GA-hMSC2–20 and GA-hMSC230) using the Illumina HiSeq2000 platform. Paired-end 
sequencing was completed on genomic DNA fragmented to an average size of 160bp. Reads 
were aligned to build Circos plots using BM-hMSC as a reference sequence. Copy number 
variants were identified by BICSeq [22]. An analysis of the Circos plots revealed frequent 
deletions and amplifications in all GSCs (Fig. 2 and Supplementary Fig. 2). In all GSCs, 
chromosome 10 showed frequent block deletions (Figure 2 and Supplementary Figure 2), 
and Chromosome 7 showed frequent amplification. Comparing the Circos plots of the 
GSC/GA-hMSCs pairs revealed at least three types of GA-hMSCs (Fig. 2 and 
Supplementary Fig. 2). In most cases (in 6 of 10 paired samples and in the 2 unmatched 
samples), GA-hMSCs did not show any large-scale copy number variations, and the gains 
and losses that were detected in the GSCs were not detected in the GA-hMSCs (Group 1 
GA-hMSCs). In particular, block deletions of chromosome 10 or gains of chromosome 7 did 
not occur in these GA-hMSCs when compared with the GSCs, and changes in other 
chromosomes (e.g., deletions of chromosome 17, which harbors the p53 gene) that were 
present in GSCs, were not present in the GA-hMSCs in these 8 cases (GA-hMSC0818, GA-
hMSC240, GA-hMSC248, GA-hMSC268, GA-hMSC280, GA-hMSC360, and unpaired 
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GA-hMSC2–20 and GA-hMSC230; Fig. 2 and Supplementary Fig. 2). We interpreted these 
results to indicate that these GA-hMSCs were distinct from the GSCs, and because they did 
not harbor mutations common to GBMs, we felt that these GA-hMSCs were probably 
normal MSCs that were recruited into the tumor. Of note is that these GA-hMSCs were only 
slightly different from normal BM-hMSCs (used as the baseline comparator) (see 
Discussion). Two less common patterns were also seen. In one case (GA-hMSC231) the 
GA-hMSC was nearly identical in copy number and structural variations to the GSC (Group 
2, Fig. 2). This finding indicates that this GA-hMSC most likely originated from the GSC 
and suggests that on rare occasions GSCs are capable of differentiating into cells that 
resemble MSCs. This finding is consistent with reports showing that GSCs are also capable 
of differentiating into other stromal cells, particularly endothelial cells, and suggests that 
tumor cells may be capable of shaping the cellular components of their microenvironment 
[29]. Lastly, three GA-hMSCs were part of a third group (GA-hMSC20, GA-hMSC262, 
GA-hMSC310) that showed block copy number variations that were not identical to their 
paired GSCs (Fig. 2 and Supplementary Fig. 2). These GA-hMSCs may represent examples 
of recruited normal MSC-like cells that acquired random and unique genomic alterations 
due to the complex genetic pressures of the tumor microenvironment and stromal 
“corruption” [30]. Alternatively, they may simply have differentiated from a unique 
unidentified GSC. Taken together, these genetic data provide evidence that although GA-
hMSCs may differentiate from GSCs, for the most part GA-hMSCs are genetically distinct 
from GSCs and, therefore, are probably recruited into the tumor from sources independent 
of GSCs.
GA-hMSCs alter the biology of GSCs in vitro
To determine whether GA-hMSCs influence the growth of gliomas, we first employed a 
coculture system using transwell plates. GSCs (GSC7-2, GSC23 or GSC240) were plated in 
the lower wells and GA-hMSCs (GA-hMSC230 and GA-hMSC240), or normal BM-
hMSCs, were placed in the upper wells, separated by 0.4µm membrane. GSC240 and GA-
hMSC240 were matched pairs. As controls, GSCs were grown in NSC medium. As a second 
control, and to compare MSCs with other stromal cells, human brain microvascular 
endothelial cells (hBMECs) were placed in the upper wells. GSC spheres cocultured with 
GA-hMSCs or BM-hMSCs were larger and exhibited significantly increased rates of 
viability compared with GSCs grown with NSC medium or hBMECs (Fig. 3a). Identical 
results were obtained when GSCs were grown in conditioned medium of GA-hMSCs or 
BM-hMSCc compared with NSC medium or conditioned medium from hBMECs (Fig. 3b). 
Similar results were obtained using another matched pair, GSC0818 and GA-hMSC0818 
(Supplementary Fig. 3a). The growth promoting effects of GA-hMSCs were independent of 
whether matched pairs or unmatched pairs of GSCs and GA-hMSCs were cocultured. 
Moreover, coculture with GA-hMSCs or BM-hMSCs significantly increased the percentage 
of GSCs in S-phase, based on EDU assays (Fig. 3c).
We next examined the self-renewal of GSCs using the neurosphere formation assay. GSCs 
were cocultured with GA-hMSC230, BM-hMSC, hBMEC, or NSC medium. After 4 days, 
single GSC-cells were plated in individual wells and assayed for sphere formation. After 
GSCs were cocultured with GA-hMSCs or BM-hMSCs, sphere formation was twice that of 
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GSCs cocultured with hBMECs or NSC medium (Fig. 3d), indicating that GA-hMSCs 
increased GSC self-renewal. This result was seen for mismatched GA-MSC/GSC pairs and 
for matched paired GSC240/GA-hMSC240 (Fig 3d). Similar results were obtained using 
another matched pair, GSC0818 and GA-hMSC0818 (Supplementary Fig. 3b).
In NSC medium, GSCs expressed the neuronal progenitor markers Musashi-1, Nestin, and 
GFAP (Fig. 3e), much like SVZ type-B progenitors, which are primitive NSCs that 
proliferate slowly [31]. Interestingly, GSCs cocultured with GA-hMSCs or BM-hMSCs 
maintained the expression of Musashi-1 and Nestin (Fig. 3e) but lost GFAP, an expression 
pattern that is similar to that of SVZ type-C stem cells, which are rapidly amplifying cells. 
Consistent with these findings, the stem cell proteins SOX2 and KLF4 were upregulated in 
GSCs cocultured with GA-hMSCs and BM-hMSCs relative to controls (Fig. 3f).
GA-hMSCs promote GSC tumorigenesis in vivo
To examine whether GA-hMSCs increase the proliferation/stemness of GSCs in vivo, 
GSC7-2 or GSC23 were cocultured for 5 days with GA-hMSC230, BM-hMSC or grown in 
NSC medium, and 104 or 105 GSCs were implanted into the brains of mice (N =10 mice/
group). The survival time of mice that were implanted with GSCs cocultured with GA-
hMSC or BM-hMSC was significantly shorter than that of mice implanted with GSCs 
cultured in NSC medium, indicating that GA-hMSCs increased the proliferation and/or 
tumorigenesis of GSCs in vivo (Fig. 4a). These results were confirmed in an independent 
experiment using the matched pair GA-hMSC240 and GSC240 (Supplementary Fig. 4a).
To determine whether GA-hMSCs specifically enhance the stemness of GSCs in vivo, we 
performed limiting-dilution assays. GSCs that were cocultured with GA-hMSCs or BM-
hMSCs were more likely to form tumors when low numbers of cells were implanted (100% 
tumorigenicity at 103 cells/mouse) compared with GSCs grown in standard NSC medium or 
cocultured with hBMECs (40% tumorigenicity at 103 cells/mouse) (Fig. 4b), supporting the 
notion that GA-hMSCs enhance the stemness of GSCs.
Next, we assessed the contribution of GA-hMSCs to the growth of GSCs when the two cell 
types were implanted simultaneously without prior coculture. This model assayed the direct 
effects of GA-hMSCs on GSCs during tumorigenesis. We injected either GSCs alone or 
GSCs in combination with GA-hMSCs, BM-hMSCs or hBMECs (N=6 mice/condition) into 
the flanks of nude mice. GSCs injected with GA-hMSCs or BM-hMSCs resulted in larger 
tumors and increased the frequency of tumor formation relative to injecting GSCs alone or 
with hBMECs (Fig. 4c; Supplementary Fig. 4b). This result was seen for both unmatched 
GA-hMSC/GSC pairs and for matched pairs GSC240/GA-hMSC240 and GSC262/GA-
hMSC262 (Supplementary Fig. 4b, c, e).
Next we further sought to determine whether the growth promoting effect of GA-hMSC was 
different for GSCs isolated from the same tumor relative to GSCs isolated from different 
tumors. We used a flank model system and found that GA-hMSC262 increased tumor 
growth to a similar extent when coinjected with matching GSC262 and unmatched GSC7-2 
(Supplementary Fig 4d). This result was confirmed with matched pairs of GA-hMSC240 
and GSC240 (Supplementary Fig. 4f).
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We then extended these “mixing’ experiments to the orthotopic intracranial model. We 
mixed equal numbers of GFP-labeled GSC7-2 and GA-hMSC230 or BM-hMSCs and 
implanted the mixtures directly into the mouse brains. We found that mice implanted with 
GSC7-2 mixed with GA-hMSCs died significantly earlier than mice implanted with GSC7-2 
alone (Fig. 4d). Compared with controls, tumors derived from GSC7-2 mixed with GA-
hMSC230 or BM-hMSCs had higher rates of proliferation based on Ki67 staining (Fig. 4e, 
left), 2), showed increased expression of the mesenchymal marker CD44 (Fig. 4e, middle 
panel), and had larger vessels (Fig. 4e, right panel).
Increases in the mesenchymal marker CD44 in the GSCs after exposure to GA-hMSCs 
prompted us to investigate whether GA-hMSCs have the ability to drive GSCs to acquire a 
mesenchymal phenotype, as defined by Philips et al. [28]. Coculture of GSC7-2 with GA-
hMSCs and BM-hMSCs increased the expression of fibronectin, CD44, TAZ, YKL40 and 
vimentin [28,32,33] (Fig. 4f). GSC23 and GSC240 also showed similar up regulation of 
these mesenchymal markers after coculture with GA-hMSCs (data not shown). Therefore, 
GA-hMSCs can drive GSCs to acquire a mesenchymal phenotype, which has been 
correlated with more aggressive behavior compared with other phenotypes [28].
IL-6 mediates GA-hMSCs effects on GSCs via the gp130/STAT3 pathway
We next investigated the molecular basis underlying the effects of GA-hMSCs on GSCs. 
BM-hMSCs, hBMECs and GA-hMSC230 and GA-hMSC240 were cultured for 48 hrs, and 
the supernatant was analyzed using a protein array. GA-hMSCs and BM-hMSCs secreted 
high level of GROα, interleukin-6 (IL-6), and interleukin-8 (IL-8) compared with hBMECs 
(Fig. 5a). ELISA confirmed these results for IL-6 and IL-8 but showed no differences for 
GRO-α or MCP-1 (Fig. 5b for IL-6; Supplementary Fig. 5 for others). ELISA also showed 
low levels of secretion of IL-6 from GSCs, including matched GSC240 (compare GA-
hMSC240 to GSC240 in Fig. 5b).
In order to determine whether any of these secreted factors altered the growth of GSCs, we 
treated GSCs (GSC7-2, GSC23, GSC240) with recombinant purified IL-6, IL-8, GRO-α, or 
MCP-1 and used a colorimetric assay to measure cell viability (WST-1). Treatment of these 
three GSC lines with IL-6 increased the viability of GSCs, whereas treatment with IL-8, 
GRO-α, and MCP-1 had no effect (Fig. 5c). To further characterize the role of IL-6, GSCs 
were exposed to increasing doses (0–10 ng/mL) of recombinant human IL-6. All GSCs 
showed a dose-dependent increase in viability after exposure to human IL-6 (Fig. 5d), 
suggesting that IL-6 mediated the increased viability observed when GSCs were cocultured 
with GA-hMSCs.
To prove that IL-6 mediates the effects of GA-hMSCs on GSCs, GSC7-2 was grown in 
cultured medium from GA-MSC230 or BM-hMSCs, with or without neutralizing antibody 
to IL-6. Anti-IL-6 antibody significantly inhibited the increased proliferation of GSCs 
induced by GA-MSC230, whereas control IgG had no effect (Fig. 5e), establishing that IL-6 
mediated the enhanced viability of GSCs.
It has been shown that IL-6 activates the JAK-STAT3-pathway [34,35], that STAT3 is 
phosphorylated in response to IL-6, and that STAT3 enhances cellular proliferation and 
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stemness [36]. In this context, western blotting showed that coculture of GSCs with BM-
hMSCs or GA-hMSCs, but not coculture with hBMECs, resulted in a significant increase in 
STAT3 phosphorylation in GSCs (Fig. 6a). Moreover, treatment with WP1066, an inhibitor 
of p-STAT3 [37], blocked GA-hMSC-mediated enhancement of proliferation and self-
renewal of GSCs in a dose-dependent manner (Fig. 6b, c), further confirming a role of p-
STAT3 in mediating the effect of GA-hMSCs on GSCs.
We sought to clarify the role of gp130, the coreceptor of IL6, in the interaction between GA-
hMSCs and GSCs by targeting the expression of gp130 using shRNA. Two different 
shRNAs against gp130 were stably expressed in GSC7-2 (creating GSC7-2-gp130shRNA1 
and GSC7-2-gp130shRNA2). Western blotting documented reduction in gp130 expression 
in both cell lines (Fig. 6d). When grown in cultured medium from GA-MSC230, both 
GSC7-2-gp130shRNA1 and GSC7-2-gp130shRNA2 showed significantly decreased 
proliferation and self-renewal (Fig. 6 e , f) relative to parental-GSC7-2, indicating that the 
effects of GA-hMSCs on GSCs were dependent on the gp130/STAT3 axis. Similarly, 
implantation of GSC7-2-gp130shRNA1 plus GA-hMSC230 or of GSC7-2-gp130shRNA2 
plus GA-hMSC230 into nude mice resulted in small tumors that were similar in size to those 
produced by GSC7-2-gp130shRNA1 and GSC7-2-gp130shRNA2, respectively, and to 
GSC7-2 parental cells (Fig. 6g). These data indicated that silencing of gp130 expression in 
GSC7-2 significantly reduced the ability of GA-hMSC230 to augment tumor growth in vivo.
DISCUSSION
We show that the stroma/microenvironment of human GBMs contains heretofore 
unidentified MSC-like cells, called GA-hMSCs, which are phenotypically similar to BM-
hMSCs, in terms of cellular morphology, surface markers, and differentiation potential, and 
differ from tumor-initiating GSCs with respect to surface markers, stem cell proteins, and 
potential for tumor formation. Importantly, most GA-hMSCs are also genetically distinct 
from GSCs, as GA-hMSCs do not harbor mutations commonly seen in GSCs, which 
suggests that GA-hMSCs are non-tumor cells recruited into GBMs, although our data also 
suggest that on rare occasions GA-hMSCs may differentiate from GSCs. Equally important, 
we show that GA-hMSCs are not mere bystanders in the GBM stroma, but instead they are 
capable of increasing the proliferation and self-renewal of GSCs based on in vitro and in 
vivo assays using both matched-pairs and unmatched GA-hMSCs and GSCs. Mechanistic 
studies indicate that the effects of GA-hMSCs are mediated at least in part by IL-6, which is 
secreted by GA-hMSCs, and which results in up regulation of p-STAT3 in GSCs.
Finding MSC-like cells in the niche where GSCs reside is unique [38]. Experimental studies 
using normal BM-hMSCs have implicated MSCs as stromal cells that support the growth of 
other solid tumors, particularly breast cancer [17]. However, the MSCs used in these studies 
were not directly isolated from primary tumors [17]. MSC-like cells have been isolated from 
human ovarian and gastric cancers [14–16], but their distinction from cancer-initiating cells 
has not been reported, and no study has analyzed the effects of MSC-like cells on cancer 
stem cells that are also obtained from patients’ tumors. In this context, we show for the first 
time that GA-hMSCs can be isolated from human glioma surgical specimens [7]. Therefore, 
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along with astrocytes, endothelial cells, and immune cells, GA-hMSCs are an important 
component of the microenvironment of glioblastomas.
According to our results from whole-genome sequencing and the differences in LOH 
patterns between matched pairs of GSCs and GA-hMSCs obtained from the same specimen, 
the majority of GA-hMSCs are genetically distinct from GSCs and typically do not harbor 
the mutations commonly seen in GSCs, e.g., losses of chromosome 10 or gains of 
chromosome 7 (Group 1 GA-hMSCs). This result suggests that most GA-hMSCs are either 
normal cells recruited to the tumor or at least are pre-existing nontumorigenic cells, similar 
to the stromal cells observed by Fomchenko et al. in animal models of GBM in which tumor 
cells and stromal cells were independently tracked [30]. This finding is consistent with the 
concept that MSCs are recruited into solid tumors either from the bone marrow or from local 
perivascular sites within the brain. The identification of relatively normal GA-hMSCs in the 
tumor is predicted from multiple studies that have shown that BM-hMSCs have a tropism 
for human gliomas and migrate/home to GBMs after intracranial or intravascular injection 
[18–20]. Although these Group 1 GA-hMSCs were similar to BM-hMSCs, which were used 
as the comparator, these GA-hMSCs harbored low-level genetic alterations that were not 
found in the BM-hMSCs. These differences between GA-hMSCs and BM-hMSCs may 
simply represent statistical variation or errors inherent to low-passage whole-genome 
sequencing. Alternatively, they may suggest that normal GA-hMSCs can be genetically 
“corrupted” due to the pressures inherent in the microenvironment of GBMs or to their 
interaction with GSCs. This concept of “stromal corruption” was demonstrated by 
Fomchenko et al. in an animal model of GBM in which cell tracing methods definitively 
identified non-tumor stromal cells with mutations similar to the tumor cells that pushed the 
stromal cell to become tumor initiating cells [30]. These animal models suggest a complex 
interaction between tumor cells and stromal cells that cannot be assessed by a “snap-shot” 
analysis of GBM stroma that is inherent to studies using human specimens, such as ours. 
Consistent with this complexity, in one of our specimens, we found that the cells identified 
phenotypically as GA-hMSCs had a genetic composition identical to the GSCs that were 
extracted from the same specimen (Group 2 GA-hMSCs). This result suggested that on rare 
occasions (~10%) it is possible for tumor cells (GSCs) to differentiate into GA-hMSCs. The 
capacity of GSCs to drive the architecture of the tumor environment by directly 
differentiating into stromal cells was shown by Wang et al., who demonstrated that GSCs 
from GBMs can differentiate into tumor vasculature [29]. Similarly, previous studies in 
breast cancer have suggested that the presence of genomic alterations similar to those 
observed in cancer cells may facilitate the tumor-promoting phenotype observed in tumor-
associated stromal cells [39–41]. Lastly, we observed GA-hMSCs that contained genetic 
alterations not identified in GSCs (Group 3 GA-hMSCs). These GA-hMSCs could represent 
an extreme form of “stromal corruption” of normal recruited BM-hMSCs or local brain 
MSCs, or it could represent differentiation of a unique GSC population in the tumor. 
Cellular tracing studies in animal models will ultimately be required to deconstruct these 
potential mechanisms. Despite this complexity, our study establishes the notion that specific 
genomic changes are not prerequisites for the GA-hMSC phenotype.
We show that GA-hMSCs are not bystanders in gliomas. Although previous reports suggest 
that endothelial cells drive the growth of GSCs [42], we did not see a significant role of 
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hBMECs. However, we found that GA-hMSCs have the capacity to promote GSC 
proliferation and stemness. We observed that GA-hMSCs’ tumor promoting ability occurred 
in heterotopic xenografts in mouse flank as well as orthotropic xenografts in mouse brain. 
Interestingly, the effects were more evident in flank tumors, where GSCs were unable to 
form tumors without GA-hMSCs, suggesting that GA-hMSCs produce a highly permissive 
environment for GSC growth. Importantly, we show that the effects occur for mismatched 
GSCs and GA-hMSCs, as well as for matched pairs (see data for GSC240/GA-hMSC240, 
GSC8-18/GA-hMSC8-18, and GSC262/GA-hMSC262). Consistent with our findings 
Sneddon et al. [12] recently showed that organ-matched mesenchymal stromal cells permit 
proliferation and self-renewal of normal progenitors cells, enabling expansion of 
endodermal cells with retention of their developmental potential. Thus mesenchymal cells 
may have an intrinsic ability to maintain the stemness of tissue specific progenitor cells, a 
property that is exploited by cancer stem cells. Altogether the changes induced by GA-
hMSCs account for the enhanced tumorigenicity seen in vivo and may explain the highly 
aggressive nature of gliomas. These results are consistent with the effects of MSCs on other 
cancers, including breast cancer, where they have been shown to enhance metastases [17]. 
Recently Ho et al. [43] reported that BM-hMSCs inhibit glioma cell growth by inhibiting 
angiogenesis, which directly contradicts our results and the results of publications by others 
[16,17,44,45]. This discrepancy may be due to the fact that Ho et al. [43] used serum-
cultured glioma cells in their experiments, whereas we used patient-derived GSCs that were 
never exposed to serum and that probably reflect human glial cells with greater fidelity than 
serum-cultured cells.
Using micro-arrays, Phillips et al. [28] and Verhaak et al. [32] showed that some 
glioblastomas express a mesenchymal phenotype [28,42]. Although it has been assumed that 
tumor cells are responsible for this phenotype, because these studies did not separate stroma 
from tumor cells, it is possible that GA-hMSCs are at least partly responsible for global 
expression profiles. We observed that GSCs cocultured with GA-hMSCs expressed 
mesenchymal markers (vimentin, CD44, TAZ, YKL40). Conversely, our flow cytometry 
data suggest that the percentage of triply-positive (CD105+/CD73+/CD90+) cells varies in 
glioma specimens. Consequently, it is possible that the mesenchymal phenotype is due both 
to GA-hMSC-induced up regulation of GSC-mesenchymal genes and to the presence of GA-
hMSCs in the stroma.
MSCs have been shown to drive tumor biology by the secretion of soluble proteins [46]. 
Consistent with this concept, we show that GA-hMSCs enhance the growth of GSCs by 
secreting IL-6. Although patients with malignant gliomas exhibit increased IL-6 [47], the 
source of this IL-6 has not been elucidated. Our results suggest that GA-hMSCs may be a 
major contributor of IL-6 in gliomas. In addition, by binding to its gp130-associated 
coreceptor, IL-6 can activate Ras-ERK, JAK1-STAT3, and PI3K [35]. We found that among 
these, STAT3 is a critical IL-6 effector in GSCs. Indeed, previous reports have implicated 
STAT3 as a driver of glioma stemness and proliferation [36]. Our results would suggest that 
the enhanced activation of STAT3 seen in gliomas may be due at least partly to the effects 
of GA-hMSCs on GSCs. Moreover, we showed that GA-hMSCs secreted factors other than 
IL-6 (e.g., Gro-α,IL-8). Although these factors did not alter GSC proliferation or stemness, 
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it is possible that they influence other functions of GSCs. This result suggests that the 
repertoire of proteins secreted by GA-hMSCs may be critical to GBM biology and demands 
further exploration.
The importance of GA-hMSCs in GSC biology opens the exciting possibility of targeting 
GA-hMSCs or the IL-6/gp130/STAT3 pathway for future cancer therapies. Blocking the 
recruitment of GA-hMSCs or blocking the cross-talk between the GA-hMSCs and GSCs via 
inhibition of IL-6, gp130, or STAT3 may represent new possibilities for glioma therapy. Of 
interest is that we and others have exploited the tropism of BM-hMSCs for gliomas by using 
BM-hMSCs as therapeutic delivery vehicles of antiglioma agents [18–20]. In this approach 
BM-hMSCs are cultured ex vivo, engineered to secrete an antiglioma protein (e.g., 
Interferon-β), and delivered back into the patient. Given that GA-hMSCs and normal BM-
hMSCs may promote tumor growth via secretion of proteins such as IL-6, critical to the 
therapeutic application of BM-hMSCs is that the normal tumor-promoting repertoire of BM-
hMSCs must be altered by genetically engineering the cells to preferentially overexpress an 
antiglioma agent, thereby subverting the natural tumor-promoting capacity of BM-hMSCs.
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SIGNIFICANCE STATEMENT
Using a translational approach the authors establish Glioma-Associated Mesenchymal 
Stem Cells (GA-MSCs) as a new, and heretofore unrecognized component of the stroma 
of human gliomas that drive the proliferation and promote the stemness of Glioma Stem 
Cells (GSCs), thereby expanding our understanding of the unique microenvironment of 
human gliomas, and establishing GA-MSC as a novel therapeutic target in gliomas.
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Figure 1. 
Isolation and characterization of GA-hMSCs from brain tumors. a–f. Representative 
confocal immunofluorescence images of a GBM specimen showing the presence of MSC-
like cells in the stroma. a. Double staining for the hMSC marker CD105 (green) and the 
endothelial marker CD31 (red) reveals CD105+ CD31- mesenchymal cells (green cells) that 
are distinct from the CD105+CD31+ endothelial cells (yellow cells) and that reside near the 
endothelial cells as pericytes and away from the endothelial cells in the tumor proper. Scale 
bar = 20 µM. b. Double staining for PDGFRβ (green) and CD105 (red), reveals significant 
numbers of PDGFRβ+CD105+ (yellow cells), consistent with the known expression of 
PDGFRβ on a subgroup of MSC-like cells. Scale bar = 50 µM. c. Double staining for 
CD105 (red) and NG2 (green) reveals that the many MSC-like cells (red) do not stain for the 
classic pericyte marker NG2. Scale bar = 20 µM. d. Double staining for CD105 (green) and 
CD133 (red) indicates that both MSC-like cells and GSCs exist independently within the 
same niche, often juxtaposed to each other. Scale bar = 20 µM. e. Double staining for 
ADAM12 (green) and CD31 (red) reveals a population of ADAM12+ cells that are distinct 
from endothelial cells. Scale bar = 50 µM. f. Double staining for ADAM12 (green).and 
CD105 (red) on an adjacent section shows expression of ADAM12 in CD105+ MSC-like 
cells (yellow cells). Scale bar = 50 µM. (for a-f, DAPI blue was used to stain nuclei). g. 
Graph showing the percentage of triply positive cells (CD105+/CD73+/CD90) in 3 fresh 
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brain tumor specimens. Tumor specimens were dissociated into single cells and analyzed by 
FACS. h. Typical growth pattern of GA-hMSC cultured in vitro in MSC medium. Spindle-
shaped cells are the classic morphology of MSCs. i. FACS analysis of typical GA-hMSC 
culture. Cells from specimen GA-hMSC231 were collected at passage 3 and analyzed for 
surface markers using antibodies to CD105, CD73, and CD90. Blue lines represent IgG 
control. Triple staining analysis revealed that the majority of cells were positive for all three 
markers. Analysis of CD34 and CD133 revealed no expression of these markers. j. 
Trilineage differentiation of GA-hMSC: GA-hMSC cells were treated with specific media 
for adipogenic differentiation (upper left), osteogenic differentiation (upper middle), and 
chondrogenic differentiation (upper right). Lower panels show staining of cells grown in 
MSC medium as a control. k. Genescan analysis of LOH of locus D10S1683 on 
chromosome 10 showing GSC240 with one allele (top) and its matched sample (from the 
same patient) GA-hMSC240 (bottom) with both alleles. l. Right, representative infiltrative 
growth pattern of typical GSCs (GSC240) grown as a xenograft in nude mouse brain. Left, 
matched GA-hMSCs (GA-hMSC240) did not form a tumor.
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Figure 2. 
GA-hMSCs are genetically heterogeneous. Representative Circos plot of genomic 
alterations using the copy number variants identified by whole-genome sequencing data of 
GA-hMSCs/GSC matched pairs and two unmatched GA-hMSCs. The outermost circle 
represents chromosomes and cytogenetic bands. The next inner circle represents copy 
number variants identified by BICSeq in which RED color indicates DNA amplifications 
while GREEN indicates genomic loss. Green arrows indicate major deletions and red arrows 
indicate major amplification events. Group 1 (example shown: GA-hMSC240/GSC240) are 
matched pairs in which the GA-hMSCs have minimal changes and do not harbor the 
deletions and amplifications seen in the GSCs (See Supplementary Fig. 2a for other pairs in 
this group). Group 2 (GA-hMSC231/GSC231) are matched pairs in which the GA-hMSCs 
and the GSCs harbor the same losses and gains. Group 3 (example GA-hMSC20/GSC20) 
are matched pairs in which the GA-hSMCs and the GSCs harbor different gains and losses 
(See Supplementary Fig. 2b for other pairs in this group).
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Figure 3. 
GA-hMSCs promote proliferation and increased self-renewal of GSCs in vitro. a. GSC7-2, 
GSC23, and GSC240 were cocultured with NSC medium (control), BM-hMSCs, GA-
hMSC230, GA-hMSC240, or hBMECs (control), and WST-1 assay was performed for cell 
proliferation after 5 days. Values represent mean ± S.D. * indicates p value is at least <0.04 
(by paired t test) compared with the NSC medium group. b. GSCs were exposed to the 
conditioned medium from different GA-hMSCs, and the proliferation of the GSCs was 
measured after 5 days. Values represent mean ± S.D. * indicates p value <0.01 (by paired t 
test) compared with the NSC medium group. c. Cell cycle distribution of GSC7-2 cocultured 
with BM-hMSCs, GA-MSC 230, and hBMECs or grown in NSC medium alone as a control. 
Red bar shows percentage of cells in S-phase. d. Indicated GSCs were cocultured with NSC 
medium (control), BM-hMSCs, GA-hMSC230, or hBMECs and assayed for sphere 
formation from single cells plated in 96-well plates (self-renewal assay). The third graph 
represents the GA-hMSC240/GSC240 matched pair. Values represent mean ± S.D. * 
indicates p value <0.008 (by paired t test) compared with NSC medium group. e. 
Representative immunofluorescence photomicrographs of GSC7-2 cocultured with GA-
hMSC230, BM-hMSCs, and hBMECs. Control is grown in standard NSC medium. 
Immunofluorescence study was performed using antibodies for nestin (left column), 
Mushashi-1 (middle column) or GFAP (right column). f. Representative western blot 
analyses of stem cell regulatory factor (SOX2 and KLF4) expression in GSC7-2 cocultured 
with NSC medium (control), BM-hMSCs, GA-hMSC230, GA-hMSC240, or hBMECs.
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Figure 4. 
GA-hMSCs enhance the growth, tumorigenicity and mesenchymal features of GSCs in vivo 
a. Survival curves showing effects of GA-hMSCs on GSCs in vivo. GSC23 (top) or GSC7-2 
(bottom) were cocultured with NSC medium (blue), GA-hMSC230 (red) or BM-hMSCs 
(green). After 7 days, GSCs (105, left or 104, right) were implanted into the brains of nude 
mice (N=10/group). The survival after coculture with BM-hMSCs or GA-hMSCs was 
significantly reduced compared with GSCs cultured in standard medium. p values (shown in 
parentheses) were calculated using a log-rank test. b. Analysis showing the increased 
tumorigenicity of GSCs (103 or 102 GSCs/mouse) cocultured with GA-hMSCs or BM-
hMSCs. c. Representative mice from flank xenograft experiments in which GSC7-2 alone 
(105 cells, far left) or GSC7-2 with BM-hMSCs (105 cells, left middle), GA-hMSCs (105 
cells, right middle), or hBMECs (105 cells, right) were injected into the left flank of nude 
mice. Elevating the skin reveals clear tumors only when BM-hMSCs or GA-hMSCs were 
injected with the GSCs. d. Graph showing survival of mice after GSCs were injected with 
GA-hMSCs orthotopically. GSC7-2GFP (105 cells) was mixed and coinjected with BM-
hMSCs (105 cells), GA-hMSC230 (105 cells), or injected alone into the brains of nude mice 
(N=10/group). The survival of mice implanted with GSC7-2 mixed with BM-hMSCs or 
GA-hMSC230 was significantly reduced compared with GSC7-2 cells implanted alone. p 
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values were calculated using a log-rank test and are shown in parentheses. e. Tumor 
specimens from animals described in section d were removed, fixed in paraffin, and 
immunostained with the shown markers. Top row shows specimens from GSC7-2 alone, 
middle row shows specimens from GSC7-2 +BM-hMSCs, and bottom row shows specimens 
form GSC7-2 +GA-hMSC230. GSCs contained green fluorescent protein (GFP), allowing 
for identification of tumor cells in the specimen using an antibody to GFP (green cells). 
Specimens were immunostained as follows: left column, GFP and the proliferation marker 
KI-67 (red); middle column, for GFP and the mesenchymal marker CD44 (red); and right 
column, for the endothelial marker CD31 (red) and PDGFR-β (green). Scale bars = 20 µM. 
f. GSC7-2 was cocultured with NSC medium (control), BM-hMSCs, GA-hMSC230, GA-
hMSC240,or hBMECs (control) for 7 days, and protein was extracted. The resulting protein 
extracts were subjected to western blotting using antibodies against the panel of 
mesenchymal markers listed. α-tubulin was used as a loading control.
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Figure 5. 
IL-6 produced by GA-hMSCs promotes GSC proliferation and self-renewal. a. GA-
hMSC230, BM-hMSCs and hBMECs were cultured in serum free medium for 3 days. The 
levels of various factors in the conditioned medium were measured by antibody array (Ray 
Biotech, GA). Each dot is a different protein (in duplicate); the intensity of the dot 
represents the amount of protein. b. ELISA for IL-6 using the conditioned medium of GA-
hMSCs, BM-hMSCs or hBMECs, as well as of GSC7-2 and GSC240. Data points represent 
means of triplicate assays. c. GSCs (as shown) were grown in the presence of GROα, IL-6, 
IL-8, or MCP-1, each at a concentration of 50 µg/ml, and proliferation was determined using 
a colorimetric assay. Only IL-6 increased the proliferation of each GSC cell line. Data 
represents mean ± S.D. * indicates p< 0.05 (by paired t test) compared with control (NSC 
medium). d. GSC240 was grown with increasing doses of IL-6, and the viability was 
assessed with the WST-1 assay. Graph shows a clear dose response of GSCs to IL-6. e. 
GSC7-2 was grown in NSC medium (black), conditioned medium from BM-hMSCs (blue), 
or conditioned medium from GA-hMSC230 (purple). To the conditioned media, inhibitory 
antibody to IL-6 (5 µg/ml), or purified IgG as a control (5 µg/ml), was added. Medium 
conditioned by BM-hMSCs or GA-hMSC230 increased proliferation, which was reversed 
by the addition of the anti-IL-6 inhibitory antibody, but not by control antibody. Data 
represent mean ± S.D. * indicates p value < 0.05 (by paired t test) compared with the group 
treated with BM-hMSC- or GA-hMSC-conditioned medium.
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Figure 6. 
Effects of GA-hMSCs on IL-6/STAT3 signaling. a. Western blot showing increase in 
phospho-STAT3 after GSC7-2 (left four lanes) or GSC23 (right four lanes) were cocultured 
with GA-hMSC230 or BM-hMSCs, but not after coculture with hBMECs. Control is growth 
in standard NSC medium. b. Pharmacological inhibition of the STAT3 pathway by WP1066 
reverses GA-hMSC230-mediated and GA-hMSC240-mediated augmentation of GSC7-2 
proliferation in a dose-dependent manner. c. Pharmacological inhibition of STAT3 pathway 
by WP1066 reverses GA-hMSC230-mediated and GA-hMSC240-mediated augmentation of 
GSC7-2 self-renewal in a dose-dependent manner. For b and c, data are mean ± S.D. * 
indicates that p was at least < 0.05 (paired t test) compared with the GA-hMSC230- or GA-
hMSC240-conditioned medium treated value. d. Down regulation of GP130 expression in 
GSC7-2 by shRNAs, as judged by western blot results. e. The shRNA-mediated decrease in 
expression of GP130 reversed GA-MSC230-mediated and GA-hMSC240-mediated 
increases in proliferation of GSC7-2. f. The shRNA-mediated decrease in expression of 
GP130 reversed GA-MSC230-mediated and GA-hMSC240-mediated increases in self-
renewal of GSC7-2. Data for e and f are mean ± S.D. * indicates that the p value is at least 
<0.003 (by paired t test) compared with GA-hMSC230-conditioned medium-treated wild-
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type GSC7-2. g. The shRNA-mediated decrease in expression of GP130 reversed the effect 
of GA-hMSC-mediated or BM-hMSC-mediated augmentation of tumor formation of 
GSC7-2 in mouse flanks.
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